Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide Capsule vs Liquid Formulation in Prostate Cancer
NCT03478904Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- Mar 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of enzalutamide in prostate cancer (PCa) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Area Under Curve at Day 42. Started Mar 2020; status: terminated.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03478904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03478904.